Spinal cord ependymoma

Summary

Spinal cord ependymoma (MONDO:0003473) is a disease. A subtype of ependymoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	spinal cord ependymoma
Mondo ID	MONDO:0003473
DOID	DOID:5503
NCIT	C3875
SNOMED CT	254949006
UMLS	C0238432
MedGen	65968
GARD	0023518
Anatomy (UBERON)	UBERON:0002240
Is cancer (heuristic)	no

Also known as: ependymoma of spinal cord · ependymoma of the spinal cord · spinal cord ependymoma

Disease family

This is a subtype of ependymoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › ependymal tumor › ependymoma › spinal cord ependymoma

Related subtypes (7): cellular ependymoma, tanycytic ependymoma, papillary ependymoma, clear cell ependymoma, brain stem ependymoma, childhood ependymoma, low grade ependymoma

Subtypes (2): adult spinal cord ependymoma, spinal ependymoma, MYCN-amplified

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.